Drug Trial Radar · NCT03654274
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
Last checked: Nov 20, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
May 22, 2018
Primary completion
Dec 16, 2021
Study completion Jan 31, 2023
Sponsor
- Lead sponsor
- Myovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 51 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on endometriosis-associated pain in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3101 or MVT-601-3102).
Conditions
- Endometriosis
Interventions
RelugolixDrug
Relugolix 40-mg tablet administered orally once daily
Estradiol/norethindrone acetateDrug
Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52Time frame: Week 52
- Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 52Time frame: Week 52
- Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104Time frame: Week 104
- Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 104Time frame: Week 104
Locations
169 sites in 20 countries. Site status is shown where the registry gives one.
Andalusia
Andalusia, Alabama
Scottsdale
Scottsdale, Arizona
Tucson
Tucson, Arizona
Tuscon
Tucson, Arizona
Canoga Park
Canoga Park, California
Los Angeles
Los Angeles, California
San Diego
San Diego, California
Greenwood Village
Greenwood Village, Colorado
Washington
Washington D.C., District of Columbia
Aventura
Aventura, Florida
Fort Myers
Fort Myers, Florida
Hialeah
Hialeah, Florida
Hialeah
Hialeah, Florida
Margate
Margate, Florida
Miami
Miami, Florida
Miami
Miami, Florida
Sarasota
Sarasota, Florida
Tampa
Tampa, Florida
Atlanta
Atlanta, Georgia
Atlanta
Atlanta, Georgia
Augusta
Augusta, Georgia
Norcross
Norcross, Georgia
Idaho Falls
Idaho Falls, Idaho
Oakbrook
Oakbrook Terrace, Illinois
Park Ridge
Park Ridge, Illinois
Shawnee
Shawnee Mission, Kansas
Marrero
Marrero, Louisiana
Towson
Towson, Maryland
Saginaw
Saginaw, Michigan
Jefferson City
Jefferson City, Missouri
St. Louis
St Louis, Missouri
Omaha
Omaha, Nebraska
Las Vegas
Las Vegas, Nevada
Durham
Durham, North Carolina
New Bern
New Bern, North Carolina
Winston Salem
Winston-Salem, North Carolina
Akron
Akron, Ohio
Columbus
Columbus, Ohio
Englewood
Englewood, Ohio
Hershey
Hershey, Pennsylvania
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.